

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
ENROLLED IN FDA TOTAL PRODUCT LIFE CYCLE
ADVISORY PROGRAM (TAP) PILOT

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that the transcatheter tricuspid valve replacement system products (“**TTVR Products**”) independently developed by the Company have been enrolled in the Total Product Life Cycle Advisory Program (“**TAP**”) pilot of the U.S. Food and Drug Administration (“**FDA**”).

TAP aims to ensure that patients in the U.S. can take the lead globally in accessing high-quality, safe, effective and innovative medical devices in the next few years by promoting early, frequent and strategic communication between the FDA and medical device manufacturers. As of September 8, 2023, the FDA has included 9 devices in the TAP pilot.

The FDA will provide diversified strategic assistance for the devices enrolled, which are of great significance to public health, including more timely pre-market communication and improving the efficiency of the pre-market review process. It is expected that this will effectively accelerate the clinical trials and commercialization progress of the TTVR Products in the U.S..

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize the TTVR Products successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, September 18, 2023

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.